Joe Hsueh
Gründer bei Act Genomics Co. Ltd.
Profil
Joe Hsueh is the founder of Act Genomics Co. Ltd.
He is currently working as the President of AnBogen Therapeutics, Inc. and as the Vice President-Corporate Operations at TaiGen Biotechnology Co., Ltd.
Mr. Hsueh has a Master's in Business Administration from Fairleigh Dickinson University and an undergraduate degree from Soochow University.
Aktive Positionen von Joe Hsueh
Unternehmen | Position | Beginn |
---|---|---|
TaiGen Biotechnology Co., Ltd.
TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan. | Geschäftsführer | 02.10.2012 |
Act Genomics Co. Ltd.
Act Genomics Co. Ltd. Hospital/Nursing ManagementHealth Services ACT Genomics Co. Ltd. develops cancer molecular information and therapeutic solutions. It specializes in oncology, cancer genomics, and bioinformatics. The company was founded by Shu Jen Chen and Hua Chien Chen in 2014 and is headquartered in Taipei, Taiwan. | Gründer | - |
AnBogen Therapeutics, Inc.
AnBogen Therapeutics, Inc. BiotechnologyHealth Technology AnBogen Therapeutics, Inc. is a clinical-stage biotech company based in Taiwan. AnBogen Therapeutics is dedicated to designing and developing precision oncology therapies to improve the lives of patients. The Taiwanese company aims to bridge the gap between research and clinical development and create breakthrough science that meaningfully changes the lives of patients. AnBogen Therapeutics' collective experience in medicinal chemistry, cancer biology, drug discovery, and clinical development enables the development of a differentiated pipeline in the field of precision oncology. AnBogen Therapeutics, Inc. was founded by a group of scientists from the National Health Research Institute. The company was founded by Tsu-An Hsu, who has been the CEO since incorporation. | Präsident | - |
Ausbildung von Joe Hsueh
Fairleigh Dickinson University | Masters Business Admin |
Soochow University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
TaiGen Biotechnology Co., Ltd.
TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan. | Health Technology |
Act Genomics Co. Ltd.
Act Genomics Co. Ltd. Hospital/Nursing ManagementHealth Services ACT Genomics Co. Ltd. develops cancer molecular information and therapeutic solutions. It specializes in oncology, cancer genomics, and bioinformatics. The company was founded by Shu Jen Chen and Hua Chien Chen in 2014 and is headquartered in Taipei, Taiwan. | Health Services |
AnBogen Therapeutics, Inc.
AnBogen Therapeutics, Inc. BiotechnologyHealth Technology AnBogen Therapeutics, Inc. is a clinical-stage biotech company based in Taiwan. AnBogen Therapeutics is dedicated to designing and developing precision oncology therapies to improve the lives of patients. The Taiwanese company aims to bridge the gap between research and clinical development and create breakthrough science that meaningfully changes the lives of patients. AnBogen Therapeutics' collective experience in medicinal chemistry, cancer biology, drug discovery, and clinical development enables the development of a differentiated pipeline in the field of precision oncology. AnBogen Therapeutics, Inc. was founded by a group of scientists from the National Health Research Institute. The company was founded by Tsu-An Hsu, who has been the CEO since incorporation. | Health Technology |